Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans.

Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans.

Tumor suppressor gene TUSC2/FUS1 (TUSC2) is frequently inactivated early in lung cancer development. TUSC2 mediates apoptosis in cancer cells but not normal cells by upregulation of the intrinsic apoptotic pathway. No drug strategies currently exist targeting loss-of-function genetic abnormalities....

Full description

Bibliographic Details
Main Authors: Charles Lu, David J Stewart, J Jack Lee, Lin Ji, Rajagopal Ramesh, Gitanjali Jayachandran, Maria I Nunez, Ignacio I Wistuba, Jeremy J Erasmus, Marshall E Hicks, Elizabeth A Grimm, James M Reuben, Veerabhadran Baladandayuthapani, Nancy S Templeton, John D McMannis, Jack A Roth
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3338819?pdf=render

Internet

http://europepmc.org/articles/PMC3338819?pdf=render

Similar Items